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Abstract 
Background: Several proangiogenic molecules have been implicated in the pathogenies of asthmatic inflammation 
and remodeling. The aim of the study was to compare the concentration of proangiogenic factors in the sera of asth‑
matic patients and in healthy subjects (HS), and to refer the concentrations to both clinical and inflammatory markers 
of the disease severity.
Methods: Serum was collected from 45 patients with severe/refractory asthma (SRA) and 51 patients with non‑
severe asthma (nSA). The control group included 30 HS. Serum concentrations of Angiopoietin‑1, Angiopoietin‑2, vas‑
cular endothelial growth factor (VEGF) and osteopontin were assessed by the enzyme‑linked immunosorbent assay.
Results: The levels of Angiopoietin‑1 (68.8 ± 2.7 vs 56.4 ± 9.3 ng/ml; p < 0.05), Angiopoietin‑2 (4.9 ± 0.35 vs 
1.38 ± 0.14 ng/ml; p < 0.0001) and VEGF were significantly higher in asthmatic patients (n = 94) as compared to HS 
(255 ± 45.4 vs 424.5 ± 27.8 pg/ml; p < 0.01). The mean serum level of Angiopoietin‑2 was found to be significantly 
higher in patients with SRA as compared to nSA patients (6.04 ± 0.46 vs 3.84 ± 0.43; p < 0.001). Angiopoietin‑2 serum 
level correlated with respiratory function and with parameters of asthma severity: the mean number of asthma exac‑
erbations in the preceding 12 months (R = 0.21; p < 0.05), mean number of emergency visits due to severe asthma 
exacerbation (R = 0.24; p < 0.04) and mean number of hospitalizations (R = 0.21; p < 0.05) or dose of inhaled gluco‑
corticosteroids taken by the patients (R = 0.36; p < 0.001).
Conclusion: Angiopoietin‑2 seems to be a crucial proangiogenic cytokine overproduced in patients with SRA char‑
acterized by repeated exacerbations and Angiopoietin‑2 serum levels can serve as a biomarker of severe asthma.
Keywords: Severe asthma, Pathogenesis, Angiopoietins
© 2016 Makowska et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Asthma has been defined as ‘‘a common chronic dis-
order of the airways that is complex and characterized 
by variable and recurring symptoms, airflow obstruc-
tion, bronchial hyperresponsiveness, and an underlying 
inflammation” [1]. Bronchial tissue remodeling, although 
not included in the definition, is another key feature of 
asthmatic airways and has been shown to correlate with 
the disease severity and contribute to the airway irre-
versibility [2]. Remodeling of microvasculature [3, 4] and 
angiogenesis, which is the growth of new blood vessels 
from existing vessels [4, 5] in the airways, are perceived 
to be the key features of the tissue remodeling in patients 
with asthma [4, 6, 7].
Angiogenesis is a process of wound healing and organ 
development taking place throughout life, and the mech-
anisms responsible for the formation of new vessels 
have been extensively studied [8–10]. The mechanisms 
associated with angiogenesis and airway remodeling are 
poorly understood but seem to be regulated by the bal-
ance between proangiogenic growth factors and angio-
static proteins [11]. In chronic inflammation associated 
with asthma the domination of proangiogenic factors 
and other mediators with proangiogenic properties have 
been observed [12]. Angiopoietins (Angiopoietin 1 and 
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Angiopoietin 2) and vascular endothelial growth factor 
(VEGF) are considered to play a leading role in angiogen-
esis, acting together to form new blood vessels [13]. It has 
been demonstrated that concentrations of angiopoietins 
are increased in induced sputum of asthmatic patients 
[14] and correlate with severity of exercise-induced 
asthma [15]. In one study, involving a small group 
of subjects elevated serum angiopoietins levels were 
found in asthma patients and have been associated with 
decreased lung function [16], suggesting that the serum 
level of proangiogenic factors may reflect ongoing asth-
matic inflammation and serve as a potential biomarker 
of the disease severity. Osteopontin is another proangio-
genic factor, which has been associated with the remod-
eling and its subepithelial expression was correlated with 
asthma severity [17].
The aim of the study was to compare serum levels of 
proangiogenic factors: Angiopoietin-1, Angiopoietin-2, 
VEGF and osteopontin in asthmatic patients and in 
healthy subjects (HS), and to refer their concentrations 
to the severity of asthma, clinical asthma phenotypes and 
inflammatory markers in serum.
Methods
Subjects
Sera were collected from 96 well characterized patients 
with bronchial asthma (mean age 45  ±  1.7  year, 38 
males and 58 females) recruited from the Asthma Clinic, 
Department of Immunology, Rheumatology and Allergy, 
Medical University of Lodz. Based on American Thoracic 
Society (ATS) Workshop 2000 definitions asthmatics 
with severe/refractory asthma (SRA) were distinguished 
[18]. Patients not fulfilling ATS criteria were referred to 
as non-severe asthma (nSA). Control group included 30 
nonatopic HS selected from the random sample of Lodz 
inhabitants (mean age 33.1  ±  1.5  year; 12 men and 18 
women) (from Ga2len SARI study [19]). Both groups 
were not different with respect to sex and rate of smok-
ers. Table 1 presents clinical characteristic of asthmatics 
and control subjects.
Ethics, consent and permission
The study was approved by local Ethical committee and 
all patients signed informed consent to the study.
Allergy skin testing and phenotypic characteristics
Atopy was determined based on the positive result of 
at least one skin prick test. In all patients skin prick 
tests were performed (Allergopharma, Reinbeck, Ger-
many) and a wheal diameter of 3 mm or more in excess 
of the negative control was considered a positive result. 
The following allergens were tested: D. pteronyssinus, 
D. farinae, cat, dog, trees, grass mix, weeds, Alternaria 
tenuis. Aspirin hypersensitivity was diagnosed based on 
convincing history of adverse reaction to non-steroidal 
anti-inflammatory drugs (NSAIDs) and confirmed by a 
bronchial challenge with lysine aspirin [20]. Body mass 
index (BMI) was calculated as weight (kg)/height (m2).
Respiratory function assessment
Respiratory function (flow-volume curve: FEV1, FEV1/
FVC, MEF 25-75) was measured with an automatic 
spirometer (ABC Pneumo 2000RS, Poland) when 
patients were without inhaled short acting b2 agonists for 
at least 8 h and long acting b2 agonists for at least 12 h. 
Airway reversibility was assessed 15 min after nebuliza-
tion of 2.5  mg of albuterol (Sterineb Salamol, Norton, 
Poland). The results were expressed as the best measure-
ment and maximal % change from baseline.
Serum mediator measurements
Concentrations of Angiopoietin-1 (sensitivity 10.3  pg/
ml), Angiopoietin-2 (sensitivity 21.3 pg/ml), VEGF (sen-
sitivity 9 pg/ml) and osteopontin (sensitivity 0.024 ng/ml) 
were assessed by enzyme-linked immunosorbent assay 
(ELISA: R&D; Minneapolis, USA). Total IgE, Eosinophil 
cationic protein (ECP) were measured in serum with 
ImmunoCAP system (Pharmacia diagnostic, Sweden).
Statistical analysis
Data are presented as mean  ±  SEMs (standard errors) 
or ±SD (standard deviation) as indicated. The data dis-
tribution was tested by Kolmogorov–Smirnov test. The 
following statistical methods were applied as appropriate 
and as indicated in the text: Spearman test to assess cor-
relation, exact Fisher test, analysis of variance Kruskal–
Wallis followed by post hoc Dunn’s multiple comparison 
test. Models of logistic regression were applied to assess 
the risk of SRA. p values <0.05 were considered to be 
significant.
Results
Phenotypic heterogeneity of asthmatic patients
Based on the ATS criteria 45 patients were diagnosed to 
have SRA and the remaining 51 patients were assigned 
to the non-severe (nSA) asthma group (mild and moder-
ate severity based on the GINA criteria) (Table 1). Patients 
in SRA group were on average older and tended to have 
longer asthma duration. However, both groups did not dif-
fer with regard to atopy status, presence of nasal polyps, 
aspirin hypersensitivity or obesity. The mean number of 
exacerbations was significantly higher in SRA group, and 
only patients belonging to this group reported interven-
tions of emergency service and/or hospitalizations during 
preceding 12  months, despite significantly higher mean 
dose of inhaled corticosteroids and the fact that majority 
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(58  %) of them had received oral glucocorticosteroids. 
Patients with SRA had lower lung function as compared to 
non-severe asthmatics. Reversibility of the airway obstruc-
tion after inhalation 2.5 mg of salbutamol was significantly 
higher in SRA as compared to nSA (Table 1).
Proangiogenic factors in serum from patient with asthma 
as compared to healthy controls
The mean levels of Angiopoietin-2 (4.9  ±  0.35 vs 
1.38  ±  0.14  ng/ml; p  <  0.0001), Angiopoietin-1 
(68.8  ±  2.7 vs 56.4  ±  9.3  ng/ml; p  <  0.05) and VEGF 
(255 ±  45.4 vs 424.5 ±  27.8  pg/ml; p  <  0.01) were sig-
nificantly higher in asthmatic patients as compared to 
HS. However, the mean osteopontin levels were sig-
nificantly lower as compared to controls (32.5 ±  2.1 vs 
47.9 ± 7.15 ng/ml; p < 0.05).
Association of Angiopoietin‑2 with severe asthma 
phenotype
When asthmatics were stratified according to the sever-
ity, the mean serum level of Angiopoietin-2 was found 
to be significantly higher in patients with SRA as com-
pared to nSA (6.04 ± 0.46 vs 3.84 ± 0.43; p < 0001), and 
in both asthma groups mean Angiopoietin-2 levels were 
higher as compared to HC (Fig. 1a). The serum levels of 
Angiopoietin-1, VEGF and osteopontin did not differ sig-
nificantly between asthmatic subgroups (Fig. 1 b–d), but 
the mean Angiopoietin-1 and VGEF levels were increase 
in both asthma groups as compared to HC.
For the whole asthma group a modest correlation 
between Angiopoietin-2 serum levels and number of 
asthma exacerbations was found (R  =  0.21; p  <  0.05) 
(Fig.  2a), and among patients with SRA Angiopoietin-2 
levels correlated with the number of emergency visits 
due to severe asthma exacerbation (R =  0.24; p  <  0.04) 
(Fig.  2b) and with the number of hospitalizations 
(R  =  0.21; p  <  0.05) (Fig.  2c). There was also a signifi-
cant correlation of Angiopoietin-2 serum level with the 
chronic dose of inhaled glucocorticosteroids taken by 
asthmatic patients (R = 0.36; p < 0.001) (Fig. 2d).
For the whole asthma group inverse correlation of 
serum Angiopoietin-2 levels with respiratory func-
tion parameters: FEV1% of predicted value (R = −0.31; 
p < 0.05) FEV1/FVC value (R = −0.21; p < 0.05) and MEF 
25-75 (R = −0.27; p  <  0.01) was found. Angiopoietin-2 
correlated also with airway obstruction reversibility 
defined as percentage of increase in FEV1 after inhala-
tion of 2.5 mg of salbutamol (R = 0.22; p < 0.05). Angi-
opoietin-2 correlated also with BMI of patients (R = 0.33; 
p < 0.001) and duration of the asthma (R = 0.2; p < 0.05).
Table 1 Characteristics asthmatic patients’
Data presented as mean ± SEM
BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GCS glucocorticosteroids, MEF maximum expiratory flow
Non severe asthma Severe/refractory asthma Statistical significance (p)
Number of patients 51 45
Age (years) 39.82 ± 2 51.13 ± 2.1 p < 0.01
Female/male 27/24 31/14 Ns
Atopy (%) 43 (84 %) 37 (82 %) Ns
Duration of asthma (years) 11.7 ± 1.4 21.7 ± 1.8 Ns
Aspirin hypersensitivity (%) 12 (24 %) 12 (27 %) Ns
Nasal polyps 15 (29 %) 11 (24 %) Ns
BMI 24.8 ± 0.58 27.60 ± 0.7 Ns
FEV1 (% of predicted) 99.7 ± 2.06 69.8 ± 2.9 p < 0.05
FEV1/FVC % 78.1 ± 1.4 61.4 ± 1.9 p < 0.001
MEF 25‑75 (% of predicted) 83.9 ± 4 38.9 ± 2.8 p < 0.001
FEV1 reversibility (%) 8.41 ± 0.99 21.7 ± 2 P < 0.001
Mean dose inhaled GCS (µg budesonide) 617 ± 35 2006 ± 42 p < 0.001
No of patients on oral GCS 0 26 (58 %) p < 0.001
Mean dose of oral GCS (mg prednisone per day) 0 4.24 ± 0.7 p < 0.001
Mean number of exacerbation during 12 months 0.51 ± 0.08 1.5 ± 0.12 p < 0.001
Mean number of interventions of emergency service 0 0.18 ± 0.05 p < 0.001
Mean number of hospitalizations during last 12 months 0 0.17 ± 0.05 p < 0.001
ECP (µg/l) 9.59 ± 1.2 15.78 ± 2.6 p = 0.04
Total IgE (kU/l) 200 ± 33.9 348 ± 72.7 p = 0.03
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Proangiogenic factors in serum and other asthma clinical 
phenotypes
In the whole asthma group (n = 96) we did not find any 
association of Angiopoietin-2 or other angiogenic factors 
with patients’ atopic status, presence of aspirin hyper-
sensitivity, BMI or smoking status. However, within SRA 
group in patients with aspirin hypersensitivity (n =  12) 
the mean VEGF serum levels were significantly higher 
as compared to aspirin tolerant individuals (n  =  33; 
543 ± 54 vs 369.2 ± 90 pg/ml; p < 0.05).
Proangiogenic factors and laboratory markers of asthma 
severity
Serum concentrations of Angiopoietin-2, VEGF, Angi-
opoietin-1 and osteopontin did not correlate with 
classical markers of asthma severity or asthmatic inflam-
mation: blood eosinophil number and serum ECP or 
total IgE levels. Significant correlations were found 
between Angiopoetin-2 and osteopontin (R  =  0.32; 
p  <  0.01), Angiopoietin-1 and osteopontin (R  =  0.29; 
p  <  0.01) or Angiopoietin-1 and VEGF (R  =  0.25; 
p < 0.05) levels.
Discussion
In this study involving relatively large and heterogene-
ous group of patients with asthma we documented that 
serum levels of Angiopoietin-2, were not only signifi-
cantly increased in the asthmatics as compared to the 
healthy control subjects randomly selected from the 
general population, but also were associated with severe 
refractory asthma phenotype. Patients with asthma, 
regardless of the diseases severity had on average almost 
threefold higher mean Angiopoietin-2 serum levels and 
significantly increased Angiopoietin-1 and VEGF serum 
concentrations, reflecting probably ongoing angiogenesis 
in the airways.
Fig. 1 The mean (±SEM) serum levels of angiogenic factors (a Angiopoietin‑2, b Angiopoietin‑2, c VEGF, d Osteopontin) in patients with severe 
asthma (SRA), non‑severe asthma (nSA) and in healthy controls (HC)
Page 5 of 7Makowska et al. Allergy Asthma Clin Immunol  (2016) 12:8 
We were able to distinguish a subpopulation of the 
asthma patients who despite high doses of oral and 
inhaled glucocorticosteroids suffered from severe asthma 
with low pulmonary function and frequent exacerba-
tions. These patients, who fulfilled the ATS criteria for 
SRA, had significantly increased Angiopoietin-2 levels 
as compared to the patients with mild/moderate asthma. 
Moreover, Angiopoietin-2 serum levels correlated with 
several clinical features of asthma severity and control 
including chronic dose of inhaled glucocorticosteroids, 
number of asthma exacerbations, emergency room inter-
ventions and even number of hospitalizations during 
the preceding year. Our results are in line with an earlier 
report of increased levels of both Angiopoietin-1 and 
2 [21, 22] in the induced sputum of severe asthmatics, 
which however did not correlate with the lung function 
tests result. In our study the increased Angiopoietin-2 
concentrations constituted a significant risk factors for 
the severe asthma comparable to total IgE or ECP levels 
in serum, which are well documented asthma severity 
markers. However, no direct correlation of the Angiopoi-
etin-2 levels with blood eosinophilia, serum ECP or total 
IgE levels was found. Other proangiogenic factors VEGF, 
Angiopoietin-1 and osteopontin did not correlate with 
asthma severity or severity serum markers.
We were able to demonstrate modest, but significant 
inverse correlation between the Angiopoietin-2 serum 
levels and FEV1, MEF 25-75 of predicted value, which 
suggests that local generation of this proangiogenic fac-
tor may have an effect on asthmatic airways function. A 
positive correlation found between Angiopoietin-1 levels 
and airway obstruction reversibility, may reflect involve-
ment of this factor in the modulation of a smooth muscle 
constriction.
Fig. 2 Correlation of Angiopoietin‑2 serum levels with a number of emergency visits, b mean number of exacerbations, c mean number of hospi‑
talizations due to asthma during last 12 months in 96 patients with asthma (Spearman rank test), d mean dose of inhaled glucocorticosteroids (mg 
of budesonide)
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In an earlier study Angiopoietin-2 rather than Angi-
opoietin-1 was associated with asthma and Angiopoi-
etin-1/Angiopoietin-2 ratio was positively correlated 
with lung function in adult asthma patients [16]. More 
recently, Angiopoietin-1 levels and Angiopoietin-1/Angi-
opoietin-2 ratio were shown to be reduced in children 
with asthma and no correlation of proangiogenic factors 
with respiratory function was found [23]. Interestingly, 
Angiopoietin-1 and Angiopoietin-2 levels were recently 
detected to be upregulated in the induced sputum from 
patients with optimally treated asthma, and seemed to 
be also related to the smoking status [22]. These not fully 
consistent observations may reflect differences in asthma 
phenotypes studied or be related to environmental influ-
ences and require further studies.
We found positive association of Angiopoietin-2 levels 
with asthma exacerbation defined as unscheduled visits 
in the clinic, emergency interventions or hospitalization. 
Although etiology of asthma exacerbation is multifac-
torial, the most common triggers are related to the res-
piratory infections. It has been previously demonstrated 
that rhinovirus infection can stimulate release of VEGF, 
although it had no impact on angiopoietin levels [24, 25]. 
Interestingly chronic bacterial infections were shown to 
stimulate production of Angiopoietin-2 [26]. Thus, it is 
likely that the association of increased serum levels of 
Angiopoietin-2 with the rate of asthma exacerbation may 
reflect a direct or non-direct release of proangiogenic 
factors in the airways by respiratory pathogens.
Angiopoietins (both Angiopoietin-1 and 2), which are 
involved in a new vessels formation in various organs are 
small molecules released from various cells. In addition, 
acting through specific Tie-2 receptor which is expressed 
not only on endothelial cells, but also on eosinophils and 
neutrophils [27, 28] angiopoietins may affect develop-
ment of inflammation [27]. Neovascularization have been 
postulated to be one of the features of airway remod-
eling and both Angiopoietin-1 and Angiopoietin-2 have 
been already implicated in the pathogenesis of bronchial 
asthma [21]. Angiopoietin-1 expression is increased in 
the asthmatic airways. Moreover, Angiopoietin-1 reduces 
production of inflammatory mediators like interleukin 5 
and interleukin 13, thus may have an anti-inflammatory 
effect in the airways [29, 20]. In contrast, Angiopoietin-2 
seems to be involved in development of airway inflam-
mation and remodeling and causes inflammation in vivo 
by promoting vascular leakage [31]. Thus, associations of 
serum angiopoietin with asthma severity markers seem 
to reflect involvement of proangiogenic factors in the 
airway inflammation and remodeling related to asthma 
pathogenesis and severity.
In our study proangiogenic factors other than Angi-
opoietin-2, did not correlate so well with asthma pheno-
types. Serum levels of VEGF were higher in asthmatics 
as compared to HS, but no correlation with the disease 
severity was found. Interestingly in our study VEGF was 
significantly increased in patients with severe asthma and 
coexisting aspirin hypersensitivity. Patients with aspirin 
exacerbated respiratory diseases (AERD) usually have 
more severe asthma and were shown to have more pro-
nounced airway remodeling [32]. It has been previously 
demonstrated that galectin-10 mRNA is overexpressed 
in peripheral blood leukocytes of AERD patients as com-
pared to aspirin tolerant asthmatics. Galectin in turn has 
been linked to angiogenesis through increasing VEGF 
production by platelets [33, 34], thus one can speculate 
the increased VEGF levels found in AERD patients may 
reflect increased ongoing angiogenesis linked to with 
galectin overexpression.
Our study have confirmed and extended previous 
observations suggesting an imbalance between vari-
ous proangiogenic factors in patients with bronchial 
asthma. Increased serum levels of proangiogenic Angi-
opoietin-2 in asthmatics and its association with clinical 
markers of asthma severity, including exacerbations, may 
reflect ongoing airway inflammation. Further studies are 
required to assess if Angiopoietin-2 serum level can serve 
as a biomarker of asthma severity and remodeling.
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